ProCE Banner Activity

Overview of CAR T-Cell Therapy in Multiple Myeloma

Slideset Download
Downloadable slideset from a live webinar on CAR T-cell therapies in multiple myeloma and the management of key adverse events, including updates from the 2022 American Society of Clinical Oncology Annual Meeting.

Released: July 08, 2022

Expiration: July 07, 2023

No longer available for credit.

Share

Faculty

Jesus G. Berdeja

Jesus G. Berdeja, MD

Director, Multiple Myeloma Program
Sarah Cannon Research Institute
Attending Physician
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Jesus G. Berdeja, MD

Director, Multiple Myeloma Program
Sarah Cannon Research Institute
Attending Physician
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Jesús G. Berdeja, MD: consultant: Bluebird, Bristol-Myers Squibb, Celgene, CRSPR Therapeutics, Janssen, Kite, Legend, SecuraBio, Takeda; research support: 2Seventy bio, AbbVie, Acetylon, Amgen, Bluebird, Bristol-Myers Squibb, C4 Therapeutics, CARsgen, Cartesian Therapeutics, Celgene, Celularity, CRISPR Therapeutics, EMD Serono, Fate Therapeutics, Genentech, GlaxoSmithKline, Ichnos Sciences, Incyte, Janssen, Karyopharm, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Zentalis.